For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $9.06 in the prior trading day, Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $8.99, down -0.77%. In other words, the price has decreased by -$0.77 from its previous closing price. On the day, 3.01 million shares were traded. NTLA stock price reached its highest trading level at $9.1344 during the session, while it also had its lowest trading level at $8.94.
Ratios:
Our goal is to gain a better understanding of NTLA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 11, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8.
JP Morgan Downgraded its Neutral to Underweight on November 07, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’25 when LEONARD JOHN M sold 88,146 shares for $9.49 per share. The transaction valued at 836,384 led to the insider holds 1,038,928 shares of the business.
LEONARD JOHN M bought 88,146 shares of NTLA for $822,402 on Dec 11 ’25. On Oct 01 ’25, another insider, Schultes Birgit C, who serves as the EVP, Chief Scientific Officer of the company, sold 31 shares for $17.38 each. As a result, the insider received 539 and left with 105,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1041311040 and an Enterprise Value of 628233024. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.10 while its Price-to-Book (P/B) ratio in mrq is 1.39. Its current Enterprise Value per Revenue stands at 10.92 whereas that against EBITDA is -1.34.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.06, which has changed by -0.25886232 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.25, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -19.04%, while the 200-Day Moving Average is calculated to be -20.60%.
Shares Statistics:
The stock has traded on average 7.09M shares per day over the past 3-months and 3119980 shares per day over the last 10 days, according to various share statistics. A total of 115.79M shares are outstanding, with a floating share count of 110.12M. Insiders hold about 4.93% of the company’s shares, while institutions hold 86.29% stake in the company. Shares short for NTLA as of 1765756800 were 40578361 with a Short Ratio of 5.72, compared to 1763078400 on 40235935. Therefore, it implies a Short% of Shares Outstanding of 40578361 and a Short% of Float of 39.300000000000004.
Earnings Estimates
The dynamic stock of Intellia Therapeutics Inc (NTLA) is currently attracting attention from 19.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.89 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.8 and -$4.11 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$3.59, with 21.0 analysts recommending between -$1.96 and -$4.41.
Revenue Estimates
A total of 23 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $68.3M, while the lowest revenue estimate was $44.65M, resulting in an average revenue estimate of $56.92M. In the same quarter a year ago, actual revenue was $57.88M
